Memphis-based US Biologic receives funding to develop orally administered flu vaccine
A Memphis-based biotech company announced in early August a partnership with a federal agency to work on a temperature stable, oral vaccine against two strains of the influenza virus. US Biologic, known for its proprietary oral-delivery platform OrisBio, produces oral vaccines and therapeutics, which are currently being used in animals to prevent zoonotic diseases. The company describes its platform as “safe, efficacious, and cost-effective for other infectious diseases with pandemic potential.”